TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that it has filed with Health Canada, a medical device amendment for the addition of the STERIZONE(R) 125L+ Sterilizer to the list of already cleared product for sale in Canada. The amendment will allow the introduction of new cycles, all offering increased speed and compatibility. The sterilizer, with the addition of these new cycles, represents a significant advancement in low temperature sterilization technology used in healthcare facilities.
"Today we are filing an amendment with Health Canada for the addition of new sterilization cycles that are consistent with our vision of creating the improved standard in healthcare sterilization. We are doing so in line with our previously committed to and communicated timeline", stated R.M. (Ric) Rumble, President and CEO of TSO3.
The new STERIZONE(R) 125L+ Sterilizer offers three cycles in a single sterilizer and is able to meet healthcare sterilization demands that previously required two or more sterilization systems. This low temperature sterilization system offers speed, high throughput, increased instrument compatibility, and cost effective sterilization, while engineered to be customer safe and eco-friendly. The new cycles accommodate general surgical instruments, short as well as long rigid and flexible endoscopes including complex multi-channel devices.